Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Drug Discovery
- Alzheimer’s disease
- cell therapy
- Herpes
- Respiratory
- Vaccine
- Disease
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 367334
The patent is titled Saponin Adjuvant.
Licensed Product means any product comprising Amyloid-13 peptide (AB42) or an active fragment thereof comprising at least 4 contiguous amino acids from Ai342 in combination with the Adjuvant. AL3 peptide is an internal fragment of 42 amino acids of a precursorprotein termed amyloid precursor protein or APP.
QS-21 is a purified plant extract used as a vaccine adjuvant. It is derived from the soap bark tree (Quillaja saponaria).
IPSCIO Record ID: 308733
For the Exclusive License, the Licensor of Sweden grants an exclusive license, with the right to grant sublicense, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.
For the Time-Limited Exclusive License, Licensor grants an exclusive, limited in time license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Time-Limited Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.
For the Non-Exclusive License, Licensor grants a nonexclusive license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Non-Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith; provided, however, that with respect to the Joint Technology.
Licensee Antigen means any antigen (a) owned or otherwise Controlled by Licensee and (b) believed to trigger an immune response causing the production of antibodies and/or cytokine or T-cell responses in humans as a defense against or treatment for a Disease Field.
Licensed Adjuvant means an adjuvant Controlled by Licensor which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology.
Licensed Product means any vaccine product containing both the Licensed Adjuvant and one or more Licensee Antigens; provided, however a Licensed Product may include a combination vaccine product for two or more Disease Fields but not a combination vaccine product for a Disease Field and a field that is not a Disease Field.
Matrix-A means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction A from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.
Matrix-C means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction C from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.
Matrix-M means a suspension of Matrix A and Matrix C particles that are combined in varying ratios of Matrix A to Matrix C.
The agreement grants Licensee license to two patent families, to import, make, have made, use, sell, offer for sale and otherwise exploit licensed vaccine products containing an adjuvant which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology, in the fields of HSV and chlamydia, and the time-limited exclusive fields of Neisseria gonorrhoeae, cytomegalovirus, or CMV, and Mycobacterium tuberculosis.
Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today, using a proprietary discovery platform, ATLAS, to rapidly design vaccines that act through T cell (or cellular) immune responses, in contrast to approved vaccines, which are designed to act primarily through B cell (or antibody) immune responses. Licensee is also developing a second T cell vaccine candidate, GEN-004 for pneumococcus, a leading cause of infectious disease mortality worldwide.
IPSCIO Record ID: 203273
Licensor hereby grants each Licensee a non-exclusive license, with the right to grant sublicenses, under the Licensed Patents to research, develop, use, have used, make, have made, offer for sale, sell, have sold, import and export Licensed Products other than Bapineuzumab Products in the Field in the Territory.
The patents relate to DNA Encoding Recombinant Antibody Molecules End Specific for Amyloid ß Peptide.
Aß Peptide shall mean P-amyloid protein which is the cleavage product of amyloid precursor protein, occurring predominantly as a (1-39) to (1-43) amino acid.
IPSCIO Record ID: 362501
For the Grant of License. when Licensee exercises the option, Licensor grants, commencing immediately upon exercise of the Option and for the term of this Agreement, a non-exclusive, license under the Licensed Patents, with the right to grant sublicenses, to develop, have developed, make, have made, use, offer to sell, sell, import and have imported Licensed Products in the Territory in the Field.
Licensees Compound means any compound, including but not limited to an antibody directed towards Beta Amyloid.
Licensed Product means any product in any dosage form, the development, manufacture, use, sale or importation of which product would, absent the grant by Licensor to Licensee of the license described herein, infringe any Valid Claim in any Licensed Patent. To avoid any doubt, Licensed Product shall include, without limitation, the Licensees Antibody currently under development for treatment of Alzheimers disease, designated x-933776A
